Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM1Z74X)

Drug Name
Tacedinaline Drug Info
Synonyms
Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide
Cross-matching ID
PubChem CID
2746
ChEBI ID
CHEMBL90195
CAS Number
CAS 112522-64-2
TTD Drug ID
D0W9NH

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Protein digestion and absorption 2.36 0.00e+0 78/103 (75.73%) COL1A1;COL6A2;COL6A1;...
ECM-receptor interaction 2.30 0.00e+0 80/88 (90.91%) COL1A1;COL6A2;COL6A1;...
Amoebiasis 2.10 0.00e+0 99/102 (97.06%) PRKCA;COL1A1;CXCL8;...
Salivary secretion 2.07 0.00e+0 76/93 (81.72%) PRKCA;LYZ;PRKACB;...
Complement and coagulation cascades 2.07 0.00e+0 76/85 (89.41%) PLAT;CFD;CFH;...
Pancreatic secretion 2.01 0.00e+0 87/102 (85.29%) PRKCA;PLA2G2A;ATP1A2;...
Carbohydrate digestion and absorption 2.01 0.00e+0 37/47 (78.72%) SLC2A5;SLC37A4;ATP1A2;...
Thyroid hormone synthesis 1.99 0.00e+0 66/75 (88%) PRKCA;PRKACB;GPX2;...
Hypertrophic cardiomyopathy 1.95 2.28e-3 81/90 (90%) TPM2;TNNC1;CACNA2D2;...
Dilated cardiomyopathy 1.94 3.08e-3 86/96 (89.58%) PRKACB;TPM2;TNNC1;...
Glutamatergic synapse 1.93 3.73e-3 97/114 (85.09%) PRKCA;PRKACB;SLC1A1;...
Proteoglycans in cancer 1.91 4.28e-3 172/205 (83.9%) LUM;PRKCA;DCN;...
Arrhythmogenic right ventricular cardiomyopathy 1.90 3.95e-3 70/77 (90.91%) CACNA2D2;ITGA6;DES;...
Rap1 signaling pathway 1.89 3.67e-3 184/210 (87.62%) PDGFRA;RAP1GAP;KIT;...
Focal adhesion 1.86 5.47e-3 180/201 (89.55%) PDGFRA;PRKCA;COL1A1;...
Aldosterone synthesis and secretion 1.86 5.13e-3 85/98 (86.73%) PRKCA;PRKACB;NR4A1;...
Amphetamine addiction 1.85 4.83e-3 57/69 (82.61%) PRKCA;PRKACB;MAOA;...
Gap junction 1.85 4.56e-3 72/88 (81.82%) PDGFRA;PRKCA;PDGFC;...
Inflammatory mediator regulation of TRP channels 1.85 4.32e-3 82/98 (83.67%) PRKCA;F2RL1;PRKACB;...
Axon guidance 1.84 5.64e-3 151/182 (82.97%) PRKCA;ABLIM1;CXCR4;...
Arachidonic acid metabolism 1.83 5.38e-3 48/61 (78.69%) LTA4H;PLA2G2A;PTGIS;...
Melanogenesis 1.82 5.13e-3 74/101 (73.27%) KIT;PRKCA;FZD6;...
Cholesterol metabolism 1.81 5.80e-3 44/50 (88%) APOB;PLTP;LIPA;...
Insulin secretion 1.80 6.41e-3 75/86 (87.21%) PRKCA;PRKACB;ATP1A2;...
Morphine addiction 1.80 6.98e-3 80/91 (87.91%) PRKCA;PRKACB;GNG11;...
Malaria 1.80 7.11e-3 44/50 (88%) CXCL8;CCL2;THBS1;...
Serotonergic synapse 1.79 7.22e-3 97/114 (85.09%) PRKCA;PRKACB;MAOA;...
Leukocyte transendothelial migration 1.78 8.80e-3 90/114 (78.95%) PRKCA;CXCR4;MMP9;...
Regulation of actin cytoskeleton 1.77 8.49e-3 185/218 (84.86%) PDGFRA;CXCR4;PDGFC;...
Aldosterone-regulated sodium reabsorption 1.77 8.90e-3 34/37 (91.89%) PRKCA;SGK1;ATP1A2;...
Propanoate metabolism -1.54 4.08e-2 30/34 (88.24%) ACOX3;DLD;MLYCD;...
RNA transport -1.54 3.98e-2 128/186 (68.82%) NCBP2;NXF3;TPR;...
Mitophagy -1.56 3.77e-2 56/68 (82.35%) E2F1;ULK1;GABARAPL2;...
Thermogenesis -1.58 3.15e-2 173/232 (74.57%) NDUFC1;MTOR;ATP5F1B;...
Prion disease -1.58 3.21e-2 209/273 (76.56%) ATP5MC1;NDUFB1;CCL5;...
Spinocerebellar ataxia -1.62 2.55e-2 128/143 (89.51%) PSMA3;PSMB2;VDAC3;...
Aminoacyl-tRNA biosynthesis -1.66 1.64e-2 15/66 (22.73%) LARS2;TARS2;SARS2;...
Pathways of neurodegeneration -1.69 1.21e-2 354/475 (74.53%) ATP5MC1;DVL1;NDUFB1;...
Fanconi anemia pathway -1.70 1.13e-2 36/54 (66.67%) ATR;CENPX;TELO2;...
Alzheimer disease -1.73 8.30e-3 279/369 (75.61%) MAPK1;NCSTN;IL1A;...
Collecting duct acid secretion -1.77 7.14e-3 22/27 (81.48%) ATP4A;ATP6V1F;ATP6V1B1;...
Cell cycle -1.78 7.58e-3 110/124 (88.71%) ORC2;E2F1;E2F4;...
Cytosolic DNA-sensing pathway -1.85 1.87e-3 52/63 (82.54%) POLR2K;IKBKG;POLR2H;...
Mismatch repair -1.92 6.67e-4 22/23 (95.65%) RFC1;MSH2;POLD1;...
Ribosome biogenesis in eukaryotes -2.00 7.18e-4 52/108 (48.15%) GTPBP4;EIF6;RPP38;...
Spliceosome -2.01 7.78e-4 101/150 (67.33%) SNRPG;DHX38;PRPF3;...
Amyotrophic lateral sclerosis -2.04 0.00e+0 267/364 (73.35%) CYC1;NDUFA1;DNAL4;...
Base excision repair -2.06 0.00e+0 29/33 (87.88%) MUTYH;LIG3;POLD1;...
RNA polymerase -2.06 0.00e+0 23/31 (74.19%) POLR2K;POLR2C;POLR2H;...
Homologous recombination -2.08 0.00e+0 35/41 (85.37%) RAD54L;POLD1;RAD51D;...
Nucleotide excision repair -2.11 0.00e+0 40/47 (85.11%) GTF2H1;GTF2H5;POLD4;...
Parkinson disease -2.17 0.00e+0 176/249 (70.68%) CYC1;NDUFA1;PSMA3;...
Oxidative phosphorylation -2.28 0.00e+0 93/133 (69.92%) COX6A1;ATP5MC3;ATP5F1E;...
Huntington disease -2.29 0.00e+0 233/306 (76.14%) CYC1;NDUFA1;DNAL4;...
Ribosome -2.31 0.00e+0 113/158 (71.52%) RPL35;RPL26;RPL37;...
DNA replication -2.37 0.00e+0 34/36 (94.44%) POLA1;POLD4;RFC4;...
Proteasome -2.57 0.00e+0 44/46 (95.65%) PSMA3;PSMB2;PSMA2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NPC-B13 CVCL_D3FG Homo sapiens 10uM XH
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HAP1 CVCL_Y019 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 BRD4 (-) 1 CVCL_SF59 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 CDK4 (-) 1 CVCL_SI36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 HDAC5 (-) 1 CVCL_SR11 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 ITGA4 (-) 1 CVCL_ST27 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 MAPK8 (-) 1 CVCL_SW99 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PIK3CA (-) 1 CVCL_TD60 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKACA (-) 1 CVCL_TG70 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKCQ (-) CVCL_TG92 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 RELA (-) 1 CVCL_TI75 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 SRC (-) 1 CVCL_TQ36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 TP53 (-) 1 CVCL_RJ70 Homo sapiens 0.66uM - 3.33uM 24H
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NPC-BM00 CVCL_B3QC Homo sapiens 10uM XH
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Dental pulp
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
iPS-DP31 3f-2 CVCL_DP83 Homo sapiens 10uM XH
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 24H
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NPC2-hTERT CVCL_B6EI Homo sapiens 10uM XH
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 6H, 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 2.22uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Pharynx, nasopharynx
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NPC-TY861 CVCL_A5WW Homo sapiens 10uM XH
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
Skin
Alzheimer's disease
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ND347327 CVCL_EZ03 Homo sapiens 10uM XH
Gaucher disease
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GD-iPS3 CVCL_C949 Homo sapiens 10uM XH
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
Unclear
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NPC-204 CVCL_A5WV Homo sapiens 10uM XH